Netcompany Group A/S
31.7.2026 18:30:00 CEST | Globenewswire | Press release
Major shareholder announcement
Major shareholder announcement
Company announcement
No. 46/2026
31 July 2026
Major shareholder announcement
Netcompany Group A/S ("Netcompany") hereby announces the following notification received pursuant to section 38, 39, and 40 of the Danish Capital Markets Act from The Goldman Sachs Group, Inc, regarding their direct and indirect holdings and voting rights in Netcompany.
On 30 July 2026, The Goldman Sachs Group, Inc informed Netcompany, that The Goldman Sachs Group, Inc on 27 July 2026 directly and indirectly controlled 2,283,985 voting rights corresponding to 4.97% of the total voting rights in the Company. Their direct and indirect voting rights at the previous announcement was 5.13%.
This announcement is in accordance with section 30 of the Danish Capital Markets Act.
For further information, please see the attached notification form.
Additional information
For additional information, please contact:
Netcompany Group A/S
Thomas Johansen, CFO, + 45 51 19 32 24
Frederikke Linde, Head of IR, +45 60 62 60 87
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG31.7.2026 22:25:23 CEST | Press release
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Strategic Partners A/S31.7.2026 18:15:00 CEST | Pressemeddelelse
Ændring af Finanskalender 2026
Vantiva31.7.2026 17:30:00 CEST | Press release
Vantiva - Notification of availability of the financial interim report for the half-year ended June 30, 2026
HYCU, Inc.31.7.2026 14:30:00 CEST | Press release
Wendy Inwood of HYCU® Spotlighted on the 2026 Women of the Channel EMEA List
Novo Nordisk A/S31.7.2026 13:20:45 CEST | Press release
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom